Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
04 2022
Historique:
revised: 04 01 2022
received: 02 12 2021
accepted: 07 01 2022
pubmed: 16 2 2022
medline: 6 4 2022
entrez: 15 2 2022
Statut: ppublish

Résumé

Iron deficiency (ID) is a common co-morbidity in patients with cardiovascular disease and contributes to impaired functional capacity. The relevance of ID in patients in recovery after acute stroke is not known. We assessed the prevalence of ID and anaemia in relation to functional capacity and to recovery during early rehabilitation after stroke. This observational study enrolled consecutively 746 patients with ischaemic or haemorrhagic stroke at in-patient early rehabilitation (age 68 ± 13 years, female 47%, ischaemic stroke 87%). Functional capacity was assessed before and after rehabilitation using Barthel index (reha-BI), motricity index (MI), trunk control test (TCT), and functional ambulatory category (FAC). ID was defined as ferritin <100 μg/L or as transferrin saturation (TSAT) < 20% if ferritin was 100- < 300 μg/L or if CrP > 5 mg/L. Anaemia was defined as Hb < 12 g/dL (women) and <13 g/dL (men). The prevalence of ID and anaemia before rehabilitation were 45% and 46%, respectively, and remained high at discharge (after 27 ± 17 days) at 40% and 48%, respectively. Patients with ID had lower functional capacity compared with patients without ID (reha-BI 20 [±86] vs. 40 [±80], MI 64 [±66] vs. 77 [±41], TCT 61 [±76] vs. 100 [±39], FAC 1 [±4] vs. 4 [±4]; median [IQR], all P < 0.001). ID was related to inflammation (OR 2.68 [95% CI 1.98-3.63], P < 0.001), female sex (OR 2.13 [95% CI 1.59-2.85], P < 0.001), haemorrhagic stroke (OR 1.70 [95% CI 1.11-2.61], P = 0.015), initial treatment on stroke unit (OR 3.59 [95% CI 1.08-11.89], P < 0.001), and anaemia (OR 2.94 [95% CI 2.18-3.96], P < 0.001), while age, BMI, and renal function were not related to ID. In adjusted analysis, ID was associated with low functional capacity in all functional scores: reha-BI (OR 1.66 [95% CI 1.08-2.54], P = 0.02), motricity index (OR 1.94 [95% CI 1.36-2.76], P < 0.001), trunk control test (OR 2.34 [95% CI] 1.64-3.32, P < 0.001) and functional ambulatory category (OR 1.77 [95% CI 1.2-2.63], P < 0.02). Functional capacity improved during rehabilitation regardless of presence of ID, but functional outcome remained significantly lower in patients with ID at the end of rehabilitation (rehab BI and MI, both P < 0.001). Iron deficiency and anaemia are common and persistent findings in patients after acute stroke. ID and anaemia are independently related to lower functional capacity after acute stroke and to poor functional outcome after rehabilitation. Regular assessment of iron status may identify patients at risk of low functional recovery.

Sections du résumé

BACKGROUND
Iron deficiency (ID) is a common co-morbidity in patients with cardiovascular disease and contributes to impaired functional capacity. The relevance of ID in patients in recovery after acute stroke is not known. We assessed the prevalence of ID and anaemia in relation to functional capacity and to recovery during early rehabilitation after stroke.
METHODS
This observational study enrolled consecutively 746 patients with ischaemic or haemorrhagic stroke at in-patient early rehabilitation (age 68 ± 13 years, female 47%, ischaemic stroke 87%). Functional capacity was assessed before and after rehabilitation using Barthel index (reha-BI), motricity index (MI), trunk control test (TCT), and functional ambulatory category (FAC). ID was defined as ferritin <100 μg/L or as transferrin saturation (TSAT) < 20% if ferritin was 100- < 300 μg/L or if CrP > 5 mg/L. Anaemia was defined as Hb < 12 g/dL (women) and <13 g/dL (men).
RESULTS
The prevalence of ID and anaemia before rehabilitation were 45% and 46%, respectively, and remained high at discharge (after 27 ± 17 days) at 40% and 48%, respectively. Patients with ID had lower functional capacity compared with patients without ID (reha-BI 20 [±86] vs. 40 [±80], MI 64 [±66] vs. 77 [±41], TCT 61 [±76] vs. 100 [±39], FAC 1 [±4] vs. 4 [±4]; median [IQR], all P < 0.001). ID was related to inflammation (OR 2.68 [95% CI 1.98-3.63], P < 0.001), female sex (OR 2.13 [95% CI 1.59-2.85], P < 0.001), haemorrhagic stroke (OR 1.70 [95% CI 1.11-2.61], P = 0.015), initial treatment on stroke unit (OR 3.59 [95% CI 1.08-11.89], P < 0.001), and anaemia (OR 2.94 [95% CI 2.18-3.96], P < 0.001), while age, BMI, and renal function were not related to ID. In adjusted analysis, ID was associated with low functional capacity in all functional scores: reha-BI (OR 1.66 [95% CI 1.08-2.54], P = 0.02), motricity index (OR 1.94 [95% CI 1.36-2.76], P < 0.001), trunk control test (OR 2.34 [95% CI] 1.64-3.32, P < 0.001) and functional ambulatory category (OR 1.77 [95% CI 1.2-2.63], P < 0.02). Functional capacity improved during rehabilitation regardless of presence of ID, but functional outcome remained significantly lower in patients with ID at the end of rehabilitation (rehab BI and MI, both P < 0.001).
CONCLUSIONS
Iron deficiency and anaemia are common and persistent findings in patients after acute stroke. ID and anaemia are independently related to lower functional capacity after acute stroke and to poor functional outcome after rehabilitation. Regular assessment of iron status may identify patients at risk of low functional recovery.

Identifiants

pubmed: 35166066
doi: 10.1002/jcsm.12927
pmc: PMC8977949
doi:

Substances chimiques

Ferritins 9007-73-2
Iron E1UOL152H7

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1036-1044

Informations de copyright

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Clin Gastroenterol Hepatol. 2020 Jun;18(7):1584-1591
pubmed: 31628998
Physiother Theory Pract. 2015 Jan;31(1):39-44
pubmed: 25096157
PLoS One. 2013 Dec 09;8(12):e82952
pubmed: 24349404
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):611-620
pubmed: 30680953
BMJ. 2019 Sep 18;366:l5101
pubmed: 31533934
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):54-62
pubmed: 30378296
Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S4-8
pubmed: 17699374
Rehabilitation (Stuttg). 2011 Dec;50(6):408-11
pubmed: 21626475
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
J Card Fail. 2011 Nov;17(11):899-906
pubmed: 22041326
Int J Environ Res Public Health. 2020 Sep 18;17(18):
pubmed: 32962047
Front Neurol. 2018 Mar 26;9:191
pubmed: 29632511
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1036-1044
pubmed: 35166066
Blood. 2019 Jan 3;133(1):40-50
pubmed: 30401705
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1789-1802
pubmed: 34554649
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):997-1006
pubmed: 32155323
Clin Neurol Neurosurg. 2007 Nov;109(9):763-9
pubmed: 17766038
Open Heart. 2020 Mar 11;7(1):e001153
pubmed: 32201585
Eur Neurol. 1980;19(6):382-9
pubmed: 7439211
N Engl J Med. 2011 May 26;364(21):2026-36
pubmed: 21612471
J Am Med Dir Assoc. 2015 Apr;16(4):272-6
pubmed: 25676847
Eur Heart J. 2017 Feb 1;38(5):362-372
pubmed: 27545647
BMJ Open. 2018 Apr 5;8(4):e019240
pubmed: 29626044
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Eur J Heart Fail. 2018 Jan;20(1):125-133
pubmed: 28436136
Nat Rev Cardiol. 2015 Nov;12(11):659-69
pubmed: 26194551
Eur J Clin Nutr. 2021 Mar;75(3):456-463
pubmed: 32901103
Stroke. 2013 Mar;44(3):591-7
pubmed: 23212165
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1501-1512
pubmed: 34498427
J Nutr Health Aging. 2012 Mar;16(3):220-4
pubmed: 22456776
Lancet Neurol. 2006 Jul;5(7):603-12
pubmed: 16781990
Int J Cardiol. 2016 Feb 15;205:6-12
pubmed: 26705670
Stroke. 2014 Dec;45(12):3675-83
pubmed: 25352483
N Engl J Med. 2009 Dec 17;361(25):2436-48
pubmed: 19920054
Arch Phys Med Rehabil. 2007 Oct;88(10):1314-9
pubmed: 17908575
J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1242-1249
pubmed: 32767518
Int J Med Sci. 2020 Aug 19;17(14):2232-2239
pubmed: 32922186
J Stroke Cerebrovasc Dis. 2003 May-Jun;12(3):119-26
pubmed: 17903915

Auteurs

Wolfram Doehner (W)

BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Department of Cardiology (Virchow Klinikum), Charité Universitätsmedizin Berlin, and German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Nadja Scherbakov (N)

BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Tim Schellenberg (T)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Ewa A Jankowska (EA)

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Institute of Heart Diseases, University Hospital, Wroclaw, Poland.

Jan F Scheitz (JF)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.

Stephan von Haehling (S)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Göttingen, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.

Michael Joebges (M)

Department of Neurology, Brandenburg Klinik, Bernau, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH